AZN Jan 2025 80.000 call
| Previous Close | 5.75 |
| Open | 5.90 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 80.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 5.75 - 5.90 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ReutersAstraZeneca says lung cancer drug trial shows no significant improvement in overall survival
Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial. The overall survival, or OS rates, in the TROPION-Lung01 trial "did not reach statistical significance", the company said in a presentation at the World Conference on Lung Cancer in San Diego. The trial compared the two treatments -- AstraZeneca's drug and chemotherapy -- of patients whose non-small cell lung cancer had returned after one or two prior treatment attempts.
Business WireDatopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
WILMINGTON, Del., September 09, 2024--Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy.
Business WireNovel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
WILMINGTON, Del., September 08, 2024--Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s proprietary computational pathology platform, quantitative continuous scoring (QCS), was predictive of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who were treated with datopotamab deruxtecan (Dato-DXd). In patients with TROP2-QCS biomarker positive tumors, datopotamab deruxtecan demonstrated a
